Moleculin Biotech（股票代码：MBRX）在近期提交给美国证券交易委员会（SEC）的文件中披露了一项重大进展。其“奇迹试验”报告显示，针对曾接受Venetoclax治疗但失败后的复发/难治性急性髓系白血病（R/R AML）患者，该试验实现了37%的盲法完全缓解率（CRC）。这一数据令人瞩目，为那些传统疗法已失效的患者带来了新的希望。试验结果基于严格的盲法评估，排除了主观偏差，进一步强化了其治疗潜力的可信度。
Moleculin Biotech（股票代码：MBRX）在近期提交给美国证券交易委员会（SEC）的文件中披露了一项重大进展。其“奇迹试验”报告显示，针对曾接受Venetoclax治疗但失败后的复发/难治性急性髓系白血病（R/R AML）患者，该试验实现了37%的盲法完全缓解率（CRC）。这一数据令人瞩目，为那些传统疗法已失效的患者带来了新的希望。试验结果基于严格的盲法评估，排除了主观偏差，进一步强化了其治疗潜力的可信度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.